Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Abstract : Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural killer (NK) and CD8(+) T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation and IFNγ secretion in mice and humans. NK cell-derived IFNγ subsequently favored upregulation of major histocompatibility complex class I molecules on tumor cells, rendering them sensitive to cytotoxic CD8(+) T cells. Accordingly, DTIC markedly enhanced cytotoxic T lymphocyte antigen 4 inhibition efficacy in vivo in an NK-dependent manner. These results underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents that relieve immunosuppression in vivo.
Type de document :
Article dans une revue
Journal of Investigative Dermatology, Nature Publishing Group: Open Access Hybrid Model Option A, 2013, 133 (2), pp.499-508. 〈10.1038/jid.2012.273〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00857892
Contributeur : Grégoire Mignot <>
Soumis le : mercredi 4 septembre 2013 - 10:54:29
Dernière modification le : dimanche 11 février 2018 - 01:15:12

Lien texte intégral

Identifiants

Collections

Citation

Alice Hervieu, Cédric Rébé, Frédérique Végran, Fanny Chalmin, Mélanie Bruchard, et al.. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.. Journal of Investigative Dermatology, Nature Publishing Group: Open Access Hybrid Model Option A, 2013, 133 (2), pp.499-508. 〈10.1038/jid.2012.273〉. 〈inserm-00857892〉

Partager

Métriques

Consultations de la notice

217